Jason Poff, MD, director of innovation deployment for artificial intelligence at Radiology Partners, explains the process he uses to evaluate medical imaging AI. 
 

New technology now being considered by the FDA for approval can capture coronary inflammation on CCTA images and provide risk assessments. What could this mean for the future of cardiac care? We spoke to one researcher to learn more.

Transfemoral TAVR is not always a viable option. In those instances, the two most effective alternatives are transcarotid access and transcaval access, according to a new SCAI expert consensus statement.

How safe is it to perform cardiac surgery on a pregnant patient? When should care teams try to deliver the baby first and then complete the procedure? A team of Mayo Clinic researchers addressed those very questions, and many others, in a new analysis. 

Cardiologist Aakriti Gupta, MD, MSc, spoke to Cardiovascular Business about the latest data and trends associated with using cerebral embolic protection devices during TAVR to lower the risk of stroke.

Lipoprotein (a) research is on the rise in recent years. Deepak Bhatt, MD, director of Mount Sinai Fuster Heart Hospital, explains why this trend is so important.

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.